Publications by authors named "Johan Harmenberg"

Claim this Profile
M
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Johan Harmenberg

Lancet Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Sara Bringhen, Peter M Voorhees, Torben Plesner, Ulf-Henrik Mellqvist, Brandi Reeves, Johan Harmenberg

Br J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Paul G Richardson, Albert Oriol, Alessandra Larocca, Joan Bladé, Michele Cavo, Johan Harmenberg

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Paul G Richardson, Sara Bringhen, Peter Voorhees, Torben Plesner, Ulf-Henrik Mellqvist, Johan Harmenberg

Lancet Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Robert Aiken, Magnus Axelson, Johan Harmenberg, Maria Klockare, Olle Larsson

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
Malin Wickström, Peter Nygren, Rolf Larsson, Johan Harmenberg, Jakob Lindberg

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial.
Georg Holgersson, Michael Bergqvist, Jonas Nilsson, Marcus Thureson, Johan Harmenberg

Asian Pac J Cancer Prev· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
Michael Bergqvist, Georg Holgersson, Igor Bondarenko, Elena Grechanaya, Alexey Maximovich, Johan Harmenberg

Acta Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.
Simon Ekman, Johan Harmenberg, Jan-Erik Frödin, Stefan Bergström, Cecilia Wassberg

Acta Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Åke Berglund, Anders Ullén, Alla Lisyanskaya, Sergey Orlov, Hans Hagberg, Johan Harmenberg

Invest New Drugs· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Georg Holgersson, Stefan Bergström, Johan Harmenberg, Magnus Ringbom, Maria Klockare

Med Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.
Simon Ekman, Jan-Erik Frödin, Johan Harmenberg, Antonina Bergman, Asa Hedlund

Acta Oncol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial.
Christopher M Hull, Johan Harmenberg, Eva Arlander, Fred Aoki, Johan Bring

J Am Acad Dermatol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of picropodophyllin and its isomer podophyllotoxin in human serum samples with electrospray ionization of hexylamine adducts by liquid chromatography-tandem mass spectrometry.
Yuko Rönquist-Nii, Staffan Eksborg, Magnus Axelson, Johan Harmenberg, Simon Ekman

J Chromatogr B Analyt Technol Biomed Life Sci· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Recurrent herpes simplex labialis infections. Possible prevention with a new therapeutic regimen].
Johan Harmenberg, Spotswood Spruance

Lakartidningen· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of ulcerative lesions by episodic treatment of recurrent herpes labialis: A literature review.
Johan Harmenberg, Bo Oberg, Spotwood Spruance

Acta Derm Venereol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Sten Nilsson, Lars Franzén, Christopher Parker, Christopher Tyrrell, René Blom, Johan Harmenberg

Lancet Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.
Christine Katlama, Jade Ghosn, Roland Tubiana, Marc Wirden, Marc-Antoine Valantin, Johan Harmenberg

AIDS· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
ME-609: a treatment for recurrent herpes simplex virus infections.
Johan G Harmenberg, Aftab R Awan, Stefan Alenius, Lars Ståhle, Anna C Erlandsson

Antivir Chem Chemother· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis